Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALUMIS INC.ALMS · Entity 4816 | Director · 10% owner | April 01, 2026 | April 03, 2026 |
| Disc Medicine, Inc.GMTX · Entity 2273 | Director · 10% owner | October 04, 2021 | October 06, 2021 |
| Latigo Biotherapeutics, Inc.LTGO · Entity 4709 | Director · 10% owner | August 10, 2026 | August 11, 2026 |
| PARDES BIOSCIENCES, INC.PRDS · Entity 110063 | Director · President and CEO · 10% owner | August 31, 2023 | August 31, 2023 |
| Quantum-Si IncQSI · Entity 6440 | Director | June 10, 2021 | June 14, 2021 |
| Theseus Pharmaceuticals, Inc.THRX · Entity 94301 | 10% owner | July 17, 2023 | July 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALUMIS INC.
Report date April 01, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2026-04-01 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-04-01 · Other · Disposed 1,176,470 · Balance 0 F1: Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Foresite Labs Affiliates 2021, LLC ("Labs Affiliates") to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2: The shares are held of record by Labs Affiliates. Foresite Labs, LLC ("Labs") is the managing member of Labs Affiliates and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), a manager of Labs, may be deemed to share voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs Affiliates, except to the extent of his pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,123,337 |
Reported balance
After 2026-04-01 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-04-01 · Other · Acquired 1,123,337 · Balance 1,123,337 F3: Represents shares received by Labs pursuant to pro rata distributions by Labs Affiliates, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. F4: The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs, except to the extent of his pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2026-04-01 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-04-01 · Other · Disposed 1,123,337 · Balance 0 F5: Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Labs to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. F4: The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs, except to the extent of his pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 680,486 |
Reported balance
After 2026-04-01 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2026-04-01 · Other · Acquired 680,486 · Balance 680,486 F6: Represents shares received by TFL Investment Holdings, LLC ("TFL") pursuant to pro rata distributions by Labs, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. F7: The shares are held of record by TFL. Tananbaum is the manager of TFL, and James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust, of which Tananbaum is a trustee, is the sole member of TFL. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,702,536 |
Reported balance
Holding disclosure · report date 2026-04-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 5,702,536 F8: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Fund V, except to the extent of his pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,908,332 |
Reported balance
Holding disclosure · report date 2026-04-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,908,332 F9: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of his pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,247,670 |
Reported balance
Holding disclosure · report date 2026-04-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 4,247,670 F10: The shares are held of record by Foresite Capital Fund VI, L.P. ("Fund VI"). Foresite Capital Management VI, LLC ("FCM VI") is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCM VI, may be deemed to have sole voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Fund VI, except to the extent of his pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 194,459 |
Reported balance
Holding disclosure · report date 2026-04-01 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 194,459 F11: The shares are held of record by Labs Co-Invest V, LLC ("Labs Co-Invest"). FCM V is the managing member of Labs Co-Invest and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs Co-Invest, except to the extent of his pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,960,337 |
Reported balance
Holding disclosure · report date 2026-04-01 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 1,960,337 F12: The shares are held of record by Foresite Labs Fund I, L.P. ("Labs Fund I"). Foresite Labs Management I, LLC ("FLM I") is the general partner of Labs Fund I and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FLM I, may be deemed to have sole voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs Fund I, except to the extent of his pecuniary interest in such securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Foresite Labs Affiliates 2021, LLC ("Labs Affiliates") to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
F2: The shares are held of record by Labs Affiliates. Foresite Labs, LLC ("Labs") is the managing member of Labs Affiliates and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), a manager of Labs, may be deemed to share voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs Affiliates, except to the extent of his pecuniary interest in such securities.
F3: Represents shares received by Labs pursuant to pro rata distributions by Labs Affiliates, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.
F4: The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs, except to the extent of his pecuniary interest in such securities.
F5: Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Labs to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.
F6: Represents shares received by TFL Investment Holdings, LLC ("TFL") pursuant to pro rata distributions by Labs, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.
F7: The shares are held of record by TFL. Tananbaum is the manager of TFL, and James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust, of which Tananbaum is a trustee, is the sole member of TFL.
F8: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Fund V, except to the extent of his pecuniary interest in such securities.
F9: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of his pecuniary interest in such securities.
F10: The shares are held of record by Foresite Capital Fund VI, L.P. ("Fund VI"). Foresite Capital Management VI, LLC ("FCM VI") is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCM VI, may be deemed to have sole voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Fund VI, except to the extent of his pecuniary interest in such securities.
F11: The shares are held of record by Labs Co-Invest V, LLC ("Labs Co-Invest"). FCM V is the managing member of Labs Co-Invest and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs Co-Invest, except to the extent of his pecuniary interest in such securities.
F12: The shares are held of record by Foresite Labs Fund I, L.P. ("Labs Fund I"). Foresite Labs Management I, LLC ("FLM I") is the general partner of Labs Fund I and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FLM I, may be deemed to have sole voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs Fund I, except to the extent of his pecuniary interest in such securities.
Disc Medicine, Inc.
Report date October 04, 2021 · Filed October 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2021-10-03 | Direct | 17,245 |
Reported balance
After 2021-10-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-10-04 · Grant · Acquired 17,245 · Balance 17,245 F1: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,500,000 |
Reported balance
Holding disclosure · report date 2021-10-04 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,500,000 F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCM V LLC") and Foresite Capital Opportunity Management V, LLC ("FCOM V LLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMV LLC, FCOMV LLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V of FCOM V and may be deemed to have sole voting and dispositive power over these shares. F3: (continued from footnote 2) Each Reporting Person disclaims the existence of a "group." Each of FCM V, FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,928,750 |
Reported balance
Holding disclosure · report date 2021-10-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,928,750 F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCM V LLC") and Foresite Capital Opportunity Management V, LLC ("FCOM V LLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMV LLC, FCOMV LLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V of FCOM V and may be deemed to have sole voting and dispositive power over these shares. F3: (continued from footnote 2) Each Reporting Person disclaims the existence of a "group." Each of FCM V, FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 411,500 |
Reported balance
Holding disclosure · report date 2021-10-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 411,500 F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCM V LLC") and Foresite Capital Opportunity Management V, LLC ("FCOM V LLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMV LLC, FCOMV LLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V of FCOM V and may be deemed to have sole voting and dispositive power over these shares. F3: (continued from footnote 2) Each Reporting Person disclaims the existence of a "group." Each of FCM V, FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.
F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCM V LLC") and Foresite Capital Opportunity Management V, LLC ("FCOM V LLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMV LLC, FCOMV LLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V of FCOM V and may be deemed to have sole voting and dispositive power over these shares.
F3: (continued from footnote 2) Each Reporting Person disclaims the existence of a "group." Each of FCM V, FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
Latigo Biotherapeutics, Inc.
Report date August 10, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,117,664 |
Reported balance
After 2026-08-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-10 · Conversion · Acquired 3,117,664 · Balance 3,117,664 F1: Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F2: The securities are held of record by Foresite Capital Fund V, L.P. (Fund V). Foresite Capital Management V, LLC (FCM V) is the general partner of Fund V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. The Reporting Person is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. Each of Fund V, FCM V and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,562,984 |
Reported balance
After 2026-08-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-08-10 · Conversion · Acquired 445,320 · Balance 3,562,984 F1: Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F2: The securities are held of record by Foresite Capital Fund V, L.P. (Fund V). Foresite Capital Management V, LLC (FCM V) is the general partner of Fund V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. The Reporting Person is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. Each of Fund V, FCM V and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,125,823 |
Reported balance
After 2026-08-10 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-08-10 · Conversion · Acquired 1,125,823 · Balance 1,125,823 F1: Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F3: The securities are held of record by Foresite Capital Fund VI, LP (Fund VI). Foresite Capital Management VI, LLC (FCM VI) is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. The Reporting Person is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of Fund VI, FCM VI and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,868,024 |
Reported balance
After 2026-08-10 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-08-10 · Conversion · Acquired 742,201 · Balance 1,868,024 F1: Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F3: The securities are held of record by Foresite Capital Fund VI, LP (Fund VI). Foresite Capital Management VI, LLC (FCM VI) is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. The Reporting Person is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of Fund VI, FCM VI and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,008,024 |
Reported balance
After 2026-08-10 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-08-10 · Purchase · Acquired 140,000 · Balance 2,008,024 F3: The securities are held of record by Foresite Capital Fund VI, LP (Fund VI). Foresite Capital Management VI, LLC (FCM VI) is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. The Reporting Person is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of Fund VI, FCM VI and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,203,800 |
Reported balance
After 2026-08-10 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2026-08-10 · Conversion · Acquired 195,776 · Balance 2,203,800 F4: Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F3: The securities are held of record by Foresite Capital Fund VI, LP (Fund VI). Foresite Capital Management VI, LLC (FCM VI) is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. The Reporting Person is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of Fund VI, FCM VI and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,117,664 |
Reported balance
After 2026-08-10 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2026-08-10 · Conversion · Acquired 3,117,664 · Balance 3,117,664 F1: Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F5: The securities are held of record by Foresite Capital Opportunity Fund V, L.P. (Opportunity Fund V). Foresite Capital Opportunity Management V, LLC (FCOM V) is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over the shares held by Opportunity Fund V. The Reporting Person is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over the securities held by Opportunity Fund V. Each of Opportunity Fund V, FCOM V and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,414,544 |
Reported balance
After 2026-08-10 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2026-08-10 · Conversion · Acquired 296,880 · Balance 3,414,544 F1: Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F5: The securities are held of record by Foresite Capital Opportunity Fund V, L.P. (Opportunity Fund V). Foresite Capital Opportunity Management V, LLC (FCOM V) is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over the shares held by Opportunity Fund V. The Reporting Person is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over the securities held by Opportunity Fund V. Each of Opportunity Fund V, FCOM V and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Series A-2 Convertible StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-10 · Conversion · Disposed 3,117,664 · Balance 0 F1: Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F2: The securities are held of record by Foresite Capital Fund V, L.P. (Fund V). Foresite Capital Management V, LLC (FCM V) is the general partner of Fund V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. The Reporting Person is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. Each of Fund V, FCM V and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-10 · Conversion · Disposed 445,320 · Balance 0 F1: Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F2: The securities are held of record by Foresite Capital Fund V, L.P. (Fund V). Foresite Capital Management V, LLC (FCM V) is the general partner of Fund V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. The Reporting Person is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. Each of Fund V, FCM V and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-08-10 · Conversion · Disposed 742,201 · Balance 0 F1: Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F3: The securities are held of record by Foresite Capital Fund VI, LP (Fund VI). Foresite Capital Management VI, LLC (FCM VI) is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. The Reporting Person is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of Fund VI, FCM VI and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-08-10 · Conversion · Disposed 296,880 · Balance 0 F1: Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F5: The securities are held of record by Foresite Capital Opportunity Fund V, L.P. (Opportunity Fund V). Foresite Capital Opportunity Management V, LLC (FCOM V) is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over the shares held by Opportunity Fund V. The Reporting Person is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over the securities held by Opportunity Fund V. Each of Opportunity Fund V, FCOM V and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-10 · Conversion · Disposed 1,125,823 · Balance 0 F1: Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F3: The securities are held of record by Foresite Capital Fund VI, LP (Fund VI). Foresite Capital Management VI, LLC (FCM VI) is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. The Reporting Person is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of Fund VI, FCM VI and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-08-10 · Conversion · Disposed 3,117,664 · Balance 0 F1: Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F5: The securities are held of record by Foresite Capital Opportunity Fund V, L.P. (Opportunity Fund V). Foresite Capital Opportunity Management V, LLC (FCOM V) is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over the shares held by Opportunity Fund V. The Reporting Person is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over the securities held by Opportunity Fund V. Each of Opportunity Fund V, FCOM V and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-08-10 · Conversion · Disposed 195,776 · Balance 0 F4: Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F3: The securities are held of record by Foresite Capital Fund VI, LP (Fund VI). Foresite Capital Management VI, LLC (FCM VI) is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. The Reporting Person is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of Fund VI, FCM VI and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date.
F2: The securities are held of record by Foresite Capital Fund V, L.P. (Fund V). Foresite Capital Management V, LLC (FCM V) is the general partner of Fund V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. The Reporting Person is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. Each of Fund V, FCM V and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
F3: The securities are held of record by Foresite Capital Fund VI, LP (Fund VI). Foresite Capital Management VI, LLC (FCM VI) is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. The Reporting Person is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of Fund VI, FCM VI and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
F4: Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock.
F5: The securities are held of record by Foresite Capital Opportunity Fund V, L.P. (Opportunity Fund V). Foresite Capital Opportunity Management V, LLC (FCOM V) is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over the shares held by Opportunity Fund V. The Reporting Person is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over the securities held by Opportunity Fund V. Each of Opportunity Fund V, FCOM V and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
PARDES BIOSCIENCES, INC.
Report date August 31, 2023 · Filed August 31, 2023
Jointly reported with FS Development Holdings II, LLC, Foresite Capital Management V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC, Foresite Capital Fund V, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-08-31 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-08-31 · Disposition to issuer · Disposed 16,813,146 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated July 16, 2023, by and among Pardes Biosciences, Inc. (the "Issuer"), MediPacific, Inc. ("Parent") and MediPacific Sub, Inc. ("Purchaser"), a wholly-owned subsidiary of Parent, pursuant to which Purchaser completed a tender offer (the "Offer") for shares of the Issuer, $0.0001 par value per share, and thereafter merged with and into the Issuer (the "Merger") effective as of August 31, 2023 (the "Effective Time"). In accordance with the terms of the Merger Agreement, at the Effective Time, the 16,813,146 shares beneficially owned by the Reporting Persons were automatically cancelled for no consideration. F2: Consisted of shares beneficially owned by FS Development Holdings II, LLC, Foresite Capital Management V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC and Foresite Capital Fund V, L.P., and of which Dr. Tananbaum may be deemed to have had a pecuniary interest. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,000 |
Reported balance
After 2023-08-31 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-08-31 · Other · Acquired 1,000 · Balance 1,000 F3: At the Effective Time, Merger Sub merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, and each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into and became one share of common stock, par value $0.0001 of the Issuer (representing 1,000 shares in the aggregate), with the Issuer surviving as a wholly owned subsidiary of Parent. F4: The shares are beneficially owned by Parent. Parent is wholly owned by Foresite Capital Opportunity Fund V, L.P. Dr. Tananbaum is the managing member of Foresite Capital Opportunity Management V, LLC, which is the general partner of Foresite Capital Opportunity Fund V, L.P. Dr. Tananbaum may be deemed to have a pecuniary interest in the shares beneficially owned by Parent. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2033-05-31 | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-31 · Disposition to issuer · Acquired 37,500 · Balance 0 F5: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2032-06-07 | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-31 · Disposition to issuer · Acquired 37,500 · Balance 0 F6: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.80 · Expires 2031-12-22 | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-31 · Disposition to issuer · Acquired 75,000 · Balance 0 F6: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated July 16, 2023, by and among Pardes Biosciences, Inc. (the "Issuer"), MediPacific, Inc. ("Parent") and MediPacific Sub, Inc. ("Purchaser"), a wholly-owned subsidiary of Parent, pursuant to which Purchaser completed a tender offer (the "Offer") for shares of the Issuer, $0.0001 par value per share, and thereafter merged with and into the Issuer (the "Merger") effective as of August 31, 2023 (the "Effective Time"). In accordance with the terms of the Merger Agreement, at the Effective Time, the 16,813,146 shares beneficially owned by the Reporting Persons were automatically cancelled for no consideration.
F2: Consisted of shares beneficially owned by FS Development Holdings II, LLC, Foresite Capital Management V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC and Foresite Capital Fund V, L.P., and of which Dr. Tananbaum may be deemed to have had a pecuniary interest.
F3: At the Effective Time, Merger Sub merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, and each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into and became one share of common stock, par value $0.0001 of the Issuer (representing 1,000 shares in the aggregate), with the Issuer surviving as a wholly owned subsidiary of Parent.
F4: The shares are beneficially owned by Parent. Parent is wholly owned by Foresite Capital Opportunity Fund V, L.P. Dr. Tananbaum is the managing member of Foresite Capital Opportunity Management V, LLC, which is the general partner of Foresite Capital Opportunity Fund V, L.P. Dr. Tananbaum may be deemed to have a pecuniary interest in the shares beneficially owned by Parent.
F5: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto.
F6: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time.
Quantum-Si Inc
Report date June 10, 2021 · Filed June 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectForesite Capital Fund IV, L.P. | 4,463,619 |
Reported balance
After 2021-06-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-06-10 · Grant · Acquired 4,463,619 · Balance 4,463,619 F1: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of February 18, 2021, by and among HighCape Capital Acquisition Corp. ("HighCape"), Tenet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HighCape ("Merger Sub"), and Quantum-Si Incorporated, a Delaware corporation ("Quantum-Si"), pursuant to which Merger Sub merged with and into Quantum-Si (the "Merger"), with Quantum-Si surviving as a wholly-owned subsidiary of HighCape (which changed its name to "Quantum-Si Incorporated", the "Issuer"), these shares were received in exchange for 5,597,015 shares of Quantum-Si Series E preferred stock. F2: Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Foresite Capital Fund IV, L.P. ("Foresite IV") and may be deemed to have sole voting and dispositive power over shares held by Foresite IV. Foresite Capital Management V, LLC ("FCM V") is the general partner of Foresite Capital Fund V, L.P. ("Foresite V") and Foresite Capital Opportunity Fund V, L.P. ("Foresite Opportunity") and may be deemed to have sole voting and dispositive power over shares held by Foresite V and Foresite Opportunity. Dr. Tananbaum is the sole managing member of FCM IV and FCM V and may be deemed to have sole voting and dispositive power over share held by Foresite IV, Foresite V, and Foresite Opportunity. Each of FCM IV, FCM V, Foresite Opportunity, and Dr. Tananbaum disclaims beneficial ownership of shares held by Foresite IV, Foresite V, and Foresite Opportunity except to the extent of any pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | IndirectForesite Capital Fund V, L.P. | 2,342,061 |
Last balance in matching sequence
After 2021-06-10 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2021-06-10 · Grant · Acquired 743,936 · Balance 743,936 F3: Received in connection with the Merger in exchange for 932,836 shares of Quantum-Si Series E preferred stock. F2: Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Foresite Capital Fund IV, L.P. ("Foresite IV") and may be deemed to have sole voting and dispositive power over shares held by Foresite IV. Foresite Capital Management V, LLC ("FCM V") is the general partner of Foresite Capital Fund V, L.P. ("Foresite V") and Foresite Capital Opportunity Fund V, L.P. ("Foresite Opportunity") and may be deemed to have sole voting and dispositive power over shares held by Foresite V and Foresite Opportunity. Dr. Tananbaum is the sole managing member of FCM IV and FCM V and may be deemed to have sole voting and dispositive power over share held by Foresite IV, Foresite V, and Foresite Opportunity. Each of FCM IV, FCM V, Foresite Opportunity, and Dr. Tananbaum disclaims beneficial ownership of shares held by Foresite IV, Foresite V, and Foresite Opportunity except to the extent of any pecuniary interest therein. Row 3 · 2021-06-10 · Grant · Acquired 1,250,000 · Balance 1,993,936 F4: Foresite V and Foresite Opportunity each purchased 1,250,000 shares of Class A common stock from the Issuer, at a price of $10.00 per share, in a private placement immediately prior to the closing of the Merger. F2: Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Foresite Capital Fund IV, L.P. ("Foresite IV") and may be deemed to have sole voting and dispositive power over shares held by Foresite IV. Foresite Capital Management V, LLC ("FCM V") is the general partner of Foresite Capital Fund V, L.P. ("Foresite V") and Foresite Capital Opportunity Fund V, L.P. ("Foresite Opportunity") and may be deemed to have sole voting and dispositive power over shares held by Foresite V and Foresite Opportunity. Dr. Tananbaum is the sole managing member of FCM IV and FCM V and may be deemed to have sole voting and dispositive power over share held by Foresite IV, Foresite V, and Foresite Opportunity. Each of FCM IV, FCM V, Foresite Opportunity, and Dr. Tananbaum disclaims beneficial ownership of shares held by Foresite IV, Foresite V, and Foresite Opportunity except to the extent of any pecuniary interest therein. Row 4 · 2021-06-10 · Grant · Acquired 348,125 · Balance 2,342,061 F5: Foresite V and Foresite Opportunity each acquired 348,125 shares of Class A common stock from the Issuer, at a price of $0.001 per share, immediately prior to the closing of the Merger. F2: Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Foresite Capital Fund IV, L.P. ("Foresite IV") and may be deemed to have sole voting and dispositive power over shares held by Foresite IV. Foresite Capital Management V, LLC ("FCM V") is the general partner of Foresite Capital Fund V, L.P. ("Foresite V") and Foresite Capital Opportunity Fund V, L.P. ("Foresite Opportunity") and may be deemed to have sole voting and dispositive power over shares held by Foresite V and Foresite Opportunity. Dr. Tananbaum is the sole managing member of FCM IV and FCM V and may be deemed to have sole voting and dispositive power over share held by Foresite IV, Foresite V, and Foresite Opportunity. Each of FCM IV, FCM V, Foresite Opportunity, and Dr. Tananbaum disclaims beneficial ownership of shares held by Foresite IV, Foresite V, and Foresite Opportunity except to the extent of any pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Foresite Capital Opportunity Fund V, L.P. | 1,598,125 |
Last balance in matching sequence
After 2021-06-10 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 5 · 2021-06-10 · Grant · Acquired 1,250,000 · Balance 1,250,000 F4: Foresite V and Foresite Opportunity each purchased 1,250,000 shares of Class A common stock from the Issuer, at a price of $10.00 per share, in a private placement immediately prior to the closing of the Merger. F2: Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Foresite Capital Fund IV, L.P. ("Foresite IV") and may be deemed to have sole voting and dispositive power over shares held by Foresite IV. Foresite Capital Management V, LLC ("FCM V") is the general partner of Foresite Capital Fund V, L.P. ("Foresite V") and Foresite Capital Opportunity Fund V, L.P. ("Foresite Opportunity") and may be deemed to have sole voting and dispositive power over shares held by Foresite V and Foresite Opportunity. Dr. Tananbaum is the sole managing member of FCM IV and FCM V and may be deemed to have sole voting and dispositive power over share held by Foresite IV, Foresite V, and Foresite Opportunity. Each of FCM IV, FCM V, Foresite Opportunity, and Dr. Tananbaum disclaims beneficial ownership of shares held by Foresite IV, Foresite V, and Foresite Opportunity except to the extent of any pecuniary interest therein. Row 6 · 2021-06-10 · Grant · Acquired 348,125 · Balance 1,598,125 F5: Foresite V and Foresite Opportunity each acquired 348,125 shares of Class A common stock from the Issuer, at a price of $0.001 per share, immediately prior to the closing of the Merger. F2: Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Foresite Capital Fund IV, L.P. ("Foresite IV") and may be deemed to have sole voting and dispositive power over shares held by Foresite IV. Foresite Capital Management V, LLC ("FCM V") is the general partner of Foresite Capital Fund V, L.P. ("Foresite V") and Foresite Capital Opportunity Fund V, L.P. ("Foresite Opportunity") and may be deemed to have sole voting and dispositive power over shares held by Foresite V and Foresite Opportunity. Dr. Tananbaum is the sole managing member of FCM IV and FCM V and may be deemed to have sole voting and dispositive power over share held by Foresite IV, Foresite V, and Foresite Opportunity. Each of FCM IV, FCM V, Foresite Opportunity, and Dr. Tananbaum disclaims beneficial ownership of shares held by Foresite IV, Foresite V, and Foresite Opportunity except to the extent of any pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | Direct | 20,512 |
Reported balance
After 2021-06-11 transaction · row 7
1 source rowRow 7 · 2021-06-11 · Grant · Acquired 20,512 · Balance 20,512 F6: Consists of RSUs. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on June 11, 2022, subject to Dr. Tananbaum's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of February 18, 2021, by and among HighCape Capital Acquisition Corp. ("HighCape"), Tenet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HighCape ("Merger Sub"), and Quantum-Si Incorporated, a Delaware corporation ("Quantum-Si"), pursuant to which Merger Sub merged with and into Quantum-Si (the "Merger"), with Quantum-Si surviving as a wholly-owned subsidiary of HighCape (which changed its name to "Quantum-Si Incorporated", the "Issuer"), these shares were received in exchange for 5,597,015 shares of Quantum-Si Series E preferred stock.
F2: Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Foresite Capital Fund IV, L.P. ("Foresite IV") and may be deemed to have sole voting and dispositive power over shares held by Foresite IV. Foresite Capital Management V, LLC ("FCM V") is the general partner of Foresite Capital Fund V, L.P. ("Foresite V") and Foresite Capital Opportunity Fund V, L.P. ("Foresite Opportunity") and may be deemed to have sole voting and dispositive power over shares held by Foresite V and Foresite Opportunity. Dr. Tananbaum is the sole managing member of FCM IV and FCM V and may be deemed to have sole voting and dispositive power over share held by Foresite IV, Foresite V, and Foresite Opportunity. Each of FCM IV, FCM V, Foresite Opportunity, and Dr. Tananbaum disclaims beneficial ownership of shares held by Foresite IV, Foresite V, and Foresite Opportunity except to the extent of any pecuniary interest therein.
F3: Received in connection with the Merger in exchange for 932,836 shares of Quantum-Si Series E preferred stock.
F4: Foresite V and Foresite Opportunity each purchased 1,250,000 shares of Class A common stock from the Issuer, at a price of $10.00 per share, in a private placement immediately prior to the closing of the Merger.
F5: Foresite V and Foresite Opportunity each acquired 348,125 shares of Class A common stock from the Issuer, at a price of $0.001 per share, immediately prior to the closing of the Merger.
F6: Consists of RSUs. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on June 11, 2022, subject to Dr. Tananbaum's continued service through the applicable vesting date.
Theseus Pharmaceuticals, Inc.
Report date July 17, 2023 · Filed July 19, 2023
Jointly reported with Foresite Capital Management V, LLC, Foresite Capital Fund V, L.P., Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,108,796 |
Reported balance
After 2023-07-17 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-07-17 · Purchase · Acquired 523,450 · Balance 4,108,796 F1: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,385,825 |
Reported balance
After 2023-07-17 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-07-17 · Purchase · Acquired 176,550 · Balance 1,385,825 F2: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F2: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
10x Genomics, Inc.
Report date May 12, 2020 · Filed May 14, 2020
Jointly reported with Foresite Capital Management I, LLC, Foresite Capital Fund I, L.P., Foresite Capital Management II, LLC, Foresite Capital Fund II, L.P.
Section 16 reporting ended · disclosed 2020-05-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,300,000 |
Reported balance
After 2020-05-12 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2020-05-12 · Conversion · Acquired 1,930,198 · Balance 4,300,000 F1: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,500,000 |
Reported balance
After 2020-05-13 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2020-05-13 · Sale · Disposed 800,000 · Balance 3,500,000 F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,350,000 |
Reported balance
After 2020-05-13 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2020-05-13 · Sale · Disposed 650,000 · Balance 2,350,000 F3: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee Footnote | 327,383 |
Reported balance
Holding disclosure · report date 2020-05-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 327,383 F4: The shares are owned by James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust ("Trust") of which Mr. Tananbaum is the trustee. Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2020-05-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-05-12 · Conversion · Disposed 1,930,198 · Balance 0 F1: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F5: The Class B Common Stock has no expiration date. F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 3,153,528 |
Reported balance
Holding disclosure · report date 2020-05-12 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 3,153,528 F1: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F5: The Class B Common Stock has no expiration date. F3: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election.
F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F3: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F4: The shares are owned by James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust ("Trust") of which Mr. Tananbaum is the trustee. Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein.
F5: The Class B Common Stock has no expiration date.
AERIE PHARMACEUTICALS INC
Report date February 27, 2020 · Filed March 02, 2020
Jointly reported with Foresite Capital Management II, LLC, Foresite Capital Fund II, L.P., Foresite Capital Fund III, L.P., Foresite Capital Fund IV, L.P., Foresite Capital Management III, LLC, Foresite Capital Management IV, LLC
Section 16 reporting ended · disclosed 2020-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,369,938 |
Reported balance
After 2020-02-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-02-27 · Sale · Disposed 302,776 · Balance 1,369,938 F1: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,925,020 |
Reported balance
After 2020-02-27 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-02-27 · Sale · Disposed 425,457 · Balance 1,925,020 F2: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,229,633 |
Reported balance
After 2020-02-27 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-02-27 · Sale · Disposed 271,767 · Balance 1,229,633 F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F2: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
Aclaris Therapeutics, Inc.
Report date November 01, 2021 · Filed November 03, 2021
Jointly reported with Foresite Capital Management III, LLC, Foresite Capital Fund III, L.P., Foresite Capital Management IV, LLC, Foresite Capital Fund IV, L.P., Foresite Capital Management V, LLC, Foresite Capital Fund V, L.P.
Section 16 reporting ended · disclosed 2021-11-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2021-11-01 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-11-01 · Other · Disposed 1,954,904 · Balance 0 F1: On November 1, 2021, Foresite Capital Fund III, L.P. ("Fund III") distributed, for no consideration, 1,954,904 shares of the Issuer's Common Stock (the "Fund III Shares") to its limited partners and to Foresite Capital Management III, LLC ("FCM III"), the general partner of Fund III, representing each such partner's pro rata interest in such Fund III Shares. On the same date, FCM III distributed, for no consideration, the Fund III Shares it received in the distribution by Fund III to its members, representing each such member's pro rata interest in such Fund III Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended. F2: The shares are owned directly by Fund III. FCM III is the general partner of Fund III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum") is the sole managing member of FCM III and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 8,276 |
Reported balance
After 2021-11-01 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2021-11-01 · Other · Acquired 8,276 · Balance 8,276 F5: Represents shares received by the James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust pursuant to pro rata distributions by Fund III and FCM III, for no consideration, of shares of the Issuer's Common Stock to their respective partners or members, as applicable. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended. F6: These shares are held of record by a family trust for which Mr. Tananbaum is a trustee. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Tananbaum, disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,399,034 |
Reported balance
Holding disclosure · report date 2021-11-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,399,034 F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,258,243 |
Reported balance
Holding disclosure · report date 2021-11-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,258,243 F4: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 1, 2021, Foresite Capital Fund III, L.P. ("Fund III") distributed, for no consideration, 1,954,904 shares of the Issuer's Common Stock (the "Fund III Shares") to its limited partners and to Foresite Capital Management III, LLC ("FCM III"), the general partner of Fund III, representing each such partner's pro rata interest in such Fund III Shares. On the same date, FCM III distributed, for no consideration, the Fund III Shares it received in the distribution by Fund III to its members, representing each such member's pro rata interest in such Fund III Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: The shares are owned directly by Fund III. FCM III is the general partner of Fund III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum") is the sole managing member of FCM III and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F4: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F5: Represents shares received by the James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust pursuant to pro rata distributions by Fund III and FCM III, for no consideration, of shares of the Issuer's Common Stock to their respective partners or members, as applicable. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended.
F6: These shares are held of record by a family trust for which Mr. Tananbaum is a trustee. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Tananbaum, disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.
Kinnate Biopharma Inc.
Report date April 03, 2024 · Filed April 05, 2024
Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 0 |
Reported balance
After 2024-04-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-04-03 · Disposition to issuer · Disposed 9,671,643 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. F2: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 0 |
Reported balance
After 2024-04-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-04-03 · Disposition to issuer · Disposed 3,525,957 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. F3: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 0 |
Reported balance
After 2024-04-03 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-04-03 · Disposition to issuer · Disposed 520,711 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. F4: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2030-12-02 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-04-03 · Disposition to issuer · Disposed 40,501 · Balance 0 F5: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.38 · Expires 2032-02-11 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-04-03 · Disposition to issuer · Disposed 20,250 · Balance 0 F5: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share.
F2: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F3: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F4: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F5: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2021 Filed Jun 14, 2021 22:55 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantClass A Common Stock | 743,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-080931 · tm2119549-22_4seq1.xml · nonDerivative · entry 2 Tananbaum James B. · CIK 0001581754 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Foresite Capital Fund V, L.P. Disclosed balance after: 743,936 F3 · price: Received in connection with the Merger in exchange for 932,836 shares of Quantum-Si Series E preferred stock. F2 · ownership.nature: Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Foresite Capital Fund IV, L.P. ("Foresite IV") and may be deemed to have sole voting and dispositive power over shares held by Foresite IV. Foresite Capital Management V, LLC ("FCM V") is the general partner of Foresite Capital Fund V, L.P. ("Foresite V") and Foresite Capital Opportunity Fund V, L.P. ("Foresite Opportunity") and may be deemed to have sole voting and dispositive power over shares held by Foresite V and Foresite Opportunity. Dr. Tananbaum is the sole managing member of FCM IV and FCM V and may be deemed to have sole voting and dispositive power over share held by Foresite IV, Foresite V, and Foresite Opportunity. Each of FCM IV, FCM V, Foresite Opportunity, and Dr. Tananbaum disclaims beneficial ownership of shares held by Foresite IV, Foresite V, and Foresite Opportunity except to the extent of any pecuniary interest therein. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 22:55 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantClass A Common Stock | 4,463,619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-080931 · tm2119549-22_4seq1.xml · nonDerivative · entry 1 Tananbaum James B. · CIK 0001581754 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Foresite Capital Fund IV, L.P. Disclosed balance after: 4,463,619 F1 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of February 18, 2021, by and among HighCape Capital Acquisition Corp. ("HighCape"), Tenet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HighCape ("Merger Sub"), and Quantum-Si Incorporated, a Delaware corporation ("Quantum-Si"), pursuant to which Merger Sub merged with and into Quantum-Si (the "Merger"), with Quantum-Si surviving as a wholly-owned subsidiary of HighCape (which changed its name to "Quantum-Si Incorporated", the "Issuer"), these shares were received in exchange for 5,597,015 shares of Quantum-Si Series E preferred stock. F2 · ownership.nature: Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Foresite Capital Fund IV, L.P. ("Foresite IV") and may be deemed to have sole voting and dispositive power over shares held by Foresite IV. Foresite Capital Management V, LLC ("FCM V") is the general partner of Foresite Capital Fund V, L.P. ("Foresite V") and Foresite Capital Opportunity Fund V, L.P. ("Foresite Opportunity") and may be deemed to have sole voting and dispositive power over shares held by Foresite V and Foresite Opportunity. Dr. Tananbaum is the sole managing member of FCM IV and FCM V and may be deemed to have sole voting and dispositive power over share held by Foresite IV, Foresite V, and Foresite Opportunity. Each of FCM IV, FCM V, Foresite Opportunity, and Dr. Tananbaum disclaims beneficial ownership of shares held by Foresite IV, Foresite V, and Foresite Opportunity except to the extent of any pecuniary interest therein. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 22:34 UTC | PARDES BIOSCIENCES, INC. FSII · Entity 110063 | PurchaseClass A Common Stock | 602,500 | $10.00 | $6,025,000.00 |
DisclosureSEC source: 0001213900-21-011174 · ownership.xml · nonDerivative · entry 1 FS Development Holdings II, LLC · CIK 0001822712 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Tananbaum James B. · CIK 0001581754 · Director · President & CEO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,500 F1 · kind: The reported shares of Class A common stock were purchased in a private placement by FS Development Holdings II, LLC (the "Sponsor") for $10.00 per share, as described under the heading "Description of Shares" in the Issuer's registration statement on Form S-1 (File No. 333-252435). F2 · ownership.direct: The Sponsor is the record holder of the shares reported herein. Foresite Capital Fund V, L.P. ("Fund V"), its general partner Foresite Capital Management V, LLC ("FCM V"), and Dr. James Tananbaum, the managing member of FCM V, have voting and investment discretion with respect to the common stock held of record by the Sponsor. Each of Fund V, FCM V, their respective members and Dr. Tananbaum disclaim beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:00 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | ConversionCommon Stock · Derivative | 2,928,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-007732 · ownership.xml · derivative · entry 4 Tananbaum James B. · CIK 0001581754 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,928,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer. F3 · derivative.exercise_date: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer. F3 · derivative.expiration_date: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer. F2 · ownership.nature: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC and Foresite Capital Opportunity Management V, LLC are general partners, respectively, of Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P., the sole shareholders of FSD Holdings. Dr. Tananbaum, in his capacity as managing member of each of the general partners, may be deemed to have voting and investment discretion over these shares. Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:00 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | ConversionCommon Stock | 2,928,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-007732 · ownership.xml · nonDerivative · entry 2 Tananbaum James B. · CIK 0001581754 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,928,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC and Foresite Capital Opportunity Management V, LLC are general partners, respectively, of Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P., the sole shareholders of FSD Holdings. Dr. Tananbaum, in his capacity as managing member of each of the general partners, may be deemed to have voting and investment discretion over these shares. Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:00 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantCommon Stock | 1,500,000 | $10.00 | $15,000,000.00 |
DisclosureSEC source: 0001213900-21-007732 · ownership.xml · nonDerivative · entry 1 Tananbaum James B. · CIK 0001581754 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,500,000 F1 · kind: Shares of common stock obtained in private placement of public securities ("PIPE") on February 5, 2021. F2 · ownership.nature: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC and Foresite Capital Opportunity Management V, LLC are general partners, respectively, of Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P., the sole shareholders of FSD Holdings. Dr. Tananbaum, in his capacity as managing member of each of the general partners, may be deemed to have voting and investment discretion over these shares. Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:12 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | ConversionSeries C Preferred Stock · Derivative | 48,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-027864 · form4.xml · derivative · entry 12 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 48,538 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 1.003350008 shares of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F6 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.003350008 shares of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F6 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.003350008 shares of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:12 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | ConversionSeries C Preferred Stock · Derivative | 145,128 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-027864 · form4.xml · derivative · entry 11 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 145,614 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 1.003350008 shares of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F6 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.003350008 shares of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F6 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.003350008 shares of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:12 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | ConversionSeries C Preferred Stock · Derivative | 157,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-027864 · form4.xml · derivative · entry 10 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 157,748 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 1.003350008 shares of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F6 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.003350008 shares of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F6 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.003350008 shares of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:12 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | ConversionSeries B Preferred Stock · Derivative | 18,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-027864 · form4.xml · derivative · entry 9 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 18,641 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:12 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | ConversionSeries B Preferred Stock · Derivative | 55,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-027864 · form4.xml · derivative · entry 8 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 55,922 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:12 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | ConversionSeries B Preferred Stock · Derivative | 2,666,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-027864 · form4.xml · derivative · entry 7 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,666,002 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:12 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | ConversionSeries A Preferred Stock · Derivative | 99,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-027864 · form4.xml · derivative · entry 6 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 99,488 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:12 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | ConversionSeries A Preferred Stock · Derivative | 298,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-027864 · form4.xml · derivative · entry 5 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 298,465 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:12 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | ConversionSeries A Preferred Stock · Derivative | 6,347,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-027864 · form4.xml · derivative · entry 4 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 6,347,893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's initial public offering of Common Stock for no additional consideration and had no expiration date. F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:12 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | ConversionCommon Stock | 166,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-027864 · form4.xml · nonDerivative · entry 3 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 291,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:12 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | ConversionCommon Stock | 500,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-027864 · form4.xml · nonDerivative · entry 2 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 875,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:12 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | ConversionCommon Stock | 9,171,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-027864 · form4.xml · nonDerivative · entry 1 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 9,671,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 21:39 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | PurchaseCommon Stock | 125,000 | $20.00 | $2,500,000.00 |
DisclosureSEC source: 0001140361-20-027407 · form4.xml · nonDerivative · entry 3 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 125,000 F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 21:39 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | PurchaseCommon Stock | 375,000 | $20.00 | $7,500,000.00 |
DisclosureSEC source: 0001140361-20-027407 · form4.xml · nonDerivative · entry 2 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 375,000 F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 21:39 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | PurchaseCommon Stock | 500,000 | $20.00 | $10,000,000.00 |
DisclosureSEC source: 0001140361-20-027407 · form4.xml · nonDerivative · entry 1 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 500,000 F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. The Reporting Person ("Dr. Tananbaum") is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 18:32 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantStock Option (right to buy) · Derivative | 40,501 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001140361-20-027400 · form4.xml · derivative · entry 1 Tananbaum James B. · CIK 0001581754 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,501 Underlying: Common Stock · 40,501 shares Expires 2030-12-02 F1 · derivative.exercise_date: The Option vests and becomes exercisable over time at the following rate: 1/36th of the total number of shares subject to the Option shall vest monthly in equal installments over three years commencing on the one-month anniversary of December 2, 2020, the Vesting Commencement Date, and each month thereafter on the same day of the month as the Vesting Commencement Date. Read SEC document |
| August 14, 2020 Filed Oct 20, 2020 00:49 UTC | Disc Medicine, Inc. FSDC · Entity 2273 | PurchaseClass A Common Stock | 441,500 | $10.00 | $4,415,000.00 |
DisclosureSEC source: 0001213900-20-032139 · ownership.xml · nonDerivative · entry 1 FS Development Holdings, LLC · CIK 0001820810 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Tananbaum James B. · CIK 0001581754 · Director · President & CEO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,500 F1 · date: The transaction was inadvertently omitted from reporting due to an administrative oversight. F2 · kind: The reported shares of Class A common stock were purchased in a private placement by FS Development Holdings, LLC (the "Sponsor") for $10.00 per share, as described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-240098). F3 · ownership.direct: The Sponsor is the record holder of the shares reported herein. Foresite Capital Fund V, L.P. ("Fund V"), its general partner Foresite Capital Management V, LLC ("FCM V"), and Dr. James Tananbaum, the managing member of FCM V, have voting and investment discretion with respect to the common stock held of record by the Sponsor. Each of Fund V, FCM V, their respective members and Dr. Tananbaum disclaim beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document |
| May 13, 2020 Filed May 14, 2020 18:01 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 650,000 | $80.13 | $52,084,500.00 |
DisclosureSEC source: 0000899243-20-013113 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,350,000 F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 13, 2020 Filed May 14, 2020 18:01 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800,000 | $80.13 | $64,104,000.00 |
DisclosureSEC source: 0000899243-20-013113 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,500,000 F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 12, 2020 Filed May 14, 2020 18:01 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 1,930,198 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-013113 · doc4.xml · derivative · entry 5 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 1,930,198 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F5 · derivative.expiration_date: The Class B Common Stock has no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 12, 2020 Filed May 14, 2020 18:01 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass A Common Stock | 1,930,198 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-013113 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,300,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 06, 2020 Filed May 8, 2020 08:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 1,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012367 · doc4.xml · derivative · entry 5 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,153,528 Underlying: Class A Common Stock · 1,500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F5 · derivative.expiration_date: The Class B Common Stock has no expiration date. F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 06, 2020 Filed May 8, 2020 08:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012367 · doc4.xml · derivative · entry 4 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,930,198 Underlying: Class A Common Stock · 500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F5 · derivative.expiration_date: The Class B Common Stock has no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 06, 2020 Filed May 8, 2020 08:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass A Common Stock | 1,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012367 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 06, 2020 Filed May 8, 2020 08:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass A Common Stock | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012367 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,369,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-011300 · doc4.xml · derivative · entry 7 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,430,198 Underlying: Class A Common Stock · 1,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F8 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F8 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F10 · derivative.expiration_date: The Class B Common Stock has no expiration date. F1 · ownership.nature: The shares were distributed on a pro rata basis by FCF I (defined below), for no consideration. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass A Common Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-011300 · doc4.xml · nonDerivative · entry 5 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,869,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 92,258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-011300 · doc4.xml · nonDerivative · entry 4 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 327,383 F6 · kind: The shares were obtained pursuant to a pro rata distribution from FCM I, for no consideration. F6 · price: The shares were obtained pursuant to a pro rata distribution from FCM I, for no consideration. F7 · ownership.nature: The shares are owned by James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust ("Trust") of which Mr. Tananbaum is the trustee. Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 178,584 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-011300 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F5 · kind: The shares were distributed on a pro rata basis by FCM I, for no consideration. F5 · price: The shares were distributed on a pro rata basis by FCM I, for no consideration. F4 · ownership.nature: The shares are owned by FCM I the general partner of FCF I and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 178,584 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-011300 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 178,584 F3 · kind: The shares were obtained pursuant to a pro rata distribution from FCF I, for no consideration. F3 · price: The shares were obtained pursuant to a pro rata distribution from FCF I, for no consideration. F4 · ownership.nature: The shares are owned by FCM I the general partner of FCF I and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 700,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-011300 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 869,802 F1 · kind: The shares were distributed on a pro rata basis by FCF I (defined below), for no consideration. F1 · price: The shares were distributed on a pro rata basis by FCF I (defined below), for no consideration. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 1,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · derivative · entry 9 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,653,528 Underlying: Class A Common Stock · 1,500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F13 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F13 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F14 · derivative.expiration_date: The Class B Common Stock has no expiration date. F4 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass A Common Stock | 1,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 8 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,500,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F4 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 109,849 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 7 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 235,125 F11 · kind: The shares represent (i) 105,367 shares obtained pursuant to a pro rata distribution from FCM I, for no consideration and (ii) 4,482 shares obtained pursuant to a pro rata distribution from FCM II, for no consideration. F11 · price: The shares represent (i) 105,367 shares obtained pursuant to a pro rata distribution from FCM I, for no consideration and (ii) 4,482 shares obtained pursuant to a pro rata distribution from FCM II, for no consideration. F12 · ownership.nature: The shares are owned by James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust ("Trust") of which Mr. Tananbaum is the trustee. Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 21,686 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 6 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F10 · kind: The shares were distributed on a pro rata basis by FCM II, for no consideration. F10 · price: The shares were distributed on a pro rata basis by FCM II, for no consideration. F9 · ownership.nature: The shares are owned by FCM II the general partner of FCF II and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 21,686 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 5 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 21,686 F8 · kind: The shares were obtained pursuant to a pro rata distribution from FCF II, for no consideration. F8 · price: The shares were obtained pursuant to a pro rata distribution from FCF II, for no consideration. F9 · ownership.nature: The shares are owned by FCM II the general partner of FCF II and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 201,115 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 4 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F7 · kind: The shares were distributed on a pro rata basis by FCM I, for no consideration. F7 · price: The shares were distributed on a pro rata basis by FCM I, for no consideration. F6 · ownership.nature: The shares are owned by FCM I the general partner of FCF I and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 201,115 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 201,115 F5 · kind: The shares were obtained pursuant to a pro rata distribution from FCF I, for no consideration. F5 · price: The shares were obtained pursuant to a pro rata distribution from FCF I, for no consideration. F6 · ownership.nature: The shares are owned by FCM I the general partner of FCF I and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 433,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: The shares were distributed on a pro rata basis by FCF II (defined below), for no consideration. F3 · price: The shares were distributed on a pro rata basis by FCF II (defined below), for no consideration. F4 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 788,317 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,569,802 F1 · kind: The shares were distributed on a pro rata basis by FCF I (defined below), for no consideration. F1 · price: The shares were distributed on a pro rata basis by FCF I (defined below), for no consideration. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 17:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 2,170,619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009578 · doc4.xml · derivative · entry 4 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,430,198 Underlying: Class A Common Stock · 2,170,619 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F5 · derivative.expiration_date: The Class B Common Stock has no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 17:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass A Common Stock | 2,170,619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009578 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,358,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 17:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 125,276 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009021 · doc4.xml · nonDerivative · entry 8 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 125,276 F8 · kind: The shares were obtained pursuant to a pro rata distribution from FCM I, for no consideration. F8 · price: The shares were obtained pursuant to a pro rata distribution from FCM I, for no consideration. F9 · ownership.nature: The shares are owned by James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust ("Trust") of which Mr. Tananbaum is the trustee. Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 17:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 241,619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009021 · doc4.xml · nonDerivative · entry 7 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F7 · kind: The shares were distributed on a pro rata basis by FCM I, for no consideration. F7 · price: The shares were distributed on a pro rata basis by FCM I, for no consideration. F6 · ownership.nature: The shares are owned by FCM I the general partner of FCF I and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.